Clinical Trials Browser

Phase 2/3 × Active not recruiting × Breast × Clear all

NCT06062810 2026-04-09

Drugs-SNPs

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT03315364 2026-04-01

OPTIMAL

Phase 2/3 Active not recruiting

Breast Neoplasms, Recurrence

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 3 FDA

Breast Neoplasms

NCT04290793 2026-01-07

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT05747794 2024-12-17

AIPAC-003

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT05889390 2024-12-03

NeoHTerMa

Phase 2/3 Active not recruiting

Hyperthermia, Breast Neoplasms

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Phase 2/3 Active not recruiting

HER2-positive Breast Cancer

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Phase 2/3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02221999 2023-08-29

SHPD002

Phase 2/3 Active not recruiting

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT01057069 2022-10-12

neo-TN

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT02568839 2020-08-13

PREDIX HER2

Phase 2/3 Active not recruiting

Breast Neoplasms